A committee of independent, expert advisers for the Food and Drug Administration voted overwhelmingly to authorize the two-dose Novavax Covid-19 vaccine yesterday, with 21 of 22 committee members voting in favor of the vaccine and one member abstaining.
The endorsement is only for a two-dose primary series in adults, not for boosters. The FDA is not obligated to follow the advice of its committee—the Vaccines and Related Biological Products Advisory Committee (VRBPAC)—but the agency typically heeds its advice. If the FDA authorizes the vaccine, the Centers for Disease Control and Prevention will need to sign off on use before it becomes available.
The decision regarding the Novavax vaccine, which is already authorized in dozens of other countries, is not a straightforward one in the US. The vaccine has some advantages over currently approved vaccines but has several strikes against…
